MANUFACTURING FACILITIES

Genome Pharmaceuticals, is a state of the art manufacturing facility that continuously invests in modern technology and the latest machinery to produce superior quality medicines as per international standards.Genome has nearly 300 pharmaceutical products registered in various therapeutic areas in

TABLETS

CAPSULES

DRY SUSPENSION

INJECTABLES

SACHETS

SOME OF OUR PRODUCTS

NEWS & EVENTS

MyMeds&Me launch mobile drug safety site

MyMeds&Me launch mobile drug safety site

By Genome Pharma  /  October 1, 2019
In time for World Patient Safety Day, MyMeds&Me has announced the launch of an “enhanced, intuitive, mobile-web version” of its...
Read More
‘New era’ of precision medicine for children with cancer

‘New era’ of precision medicine for children with cancer

By Genome Pharma  /  October 1, 2019
A new study has shown the power of genetic testing to pick out the best drugs for children with cancer...
Read More
MHRA clarifies position on off-label Avastin

MHRA clarifies position on off-label Avastin

By Genome Pharma  /  October 1, 2019
The Medicines and Healthcare products Regulatory Agency (MHRA) has clarified its position on the use of Roche's Avastin off-label as...
Read More
GW’s cannabinoid Epidyolex wins EU approva

GW’s cannabinoid Epidyolex wins EU approva

By Genome Pharma  /  October 1, 2019
GW Pharma has bagged a landmark approval for its cannabinoid Epidyolex, with European regulators clearing its use for the treatment...
Read More
Evotec links with Takeda

Evotec links with Takeda

By Genome Pharma  /  October 1, 2019
Evotec has entered into a strategic, multi-year drug discovery collaboration with Takeda, which aims to establish at least five drug...
Read More
Novartis’ Aimovig unlikely to be NHS funded for migraine

Novartis’ Aimovig unlikely to be NHS funded for migraine

By Genome Pharma  /  October 1, 2019
It is looking unlikely that Novartis' Aimovig (erenumab) will be funded by the National Health Service to prevent migraine. The...
Read More
Positive PhIII data for Jazz sleep disorder drug

Positive PhIII data for Jazz sleep disorder drug

By Genome Pharma  /  October 1, 2019
Ireland's Jazz Pharmaceuticals has unveiled positive results from a late-stage study assessing JZP-258 for the treatment of cataplexy and excessive...
Read More